Interestingly, the ghrelin receptor has been observed to increase cardiac failure and certain types of cancer, including carcinomas
These are described mechanisms from preclinical and early research, not established therapeutic outcomes
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants
This is due to the longer duration of effect of the long-acting medication compared to short-acting agonists
And some of these studies in rats involved a complete transection, not just a partial tear, but a complete cut of a given ligament or tendon or nerve pathway